Literature DB >> 21905954

Mesenchymal stromal cells derived from CD271(+) bone marrow mononuclear cells exert potent allosuppressive properties.

Zyrafete Kuçi1, Selim Kuçi, Susanne Zircher, Stefanie Koller, Ralf Schubert, Halvard Bönig, Reinhard Henschler, Ralf Lieberz, Thomas Klingebiel, Peter Bader.   

Abstract

BACKGROUND AIMS. Because data on the immunosuppressive effect of different subsets of mesenchymal stromal cells (MSC) are sparse, we investigated the molecular and cellular mechanisms underlying the allosuppressive effect of MSC generated from bone marrow CD271(+) cells (CD271-MSC) and asked whether this potential is comparable with that of MSC generated through plastic adherence (PA-MSC). METHODS. The immunosuppressive effect of CD271-MSC on the allogeneic reaction was investigated by mixed lymphocyte reaction (MLR). RESULTS. CD271-MSC significantly suppressed the alloantigen-induced proliferation of mononuclear cells (MNC) of two HLA-disparate donors at all MSC:MNC ratios, 1:1, 1:2 and 1:10. They also demonstrated a significantly higher allosuppression than PA-MSC at an MSC:MNC ratio of 1:1. This inhibitory effect was associated with significantly elevated levels of prostaglandin E2 (PGE2) at ratios of 1:1 and 1:2 (about 4-fold), but not at a ratio of 1:10. Indomethacin, and inhibitor of cyclooxygenase-1 and 2 necessary for the biosynthesis of PGE2, mitigated suppressive effects of CD271-MSC only at a ratio of 1:1, indicating that PGE2 is not involved in MSC-mediated inhibition when allogeneic MNC are in excess. The increase of PGE2 was associated with a significant decrease of pro-inflammatory cytokine levels (interferon-gamma and tumor necrosis-alpha), while no changes in levels of interleukin-10, soluble HLA-G and nitric oxide were observed. In addition, CD271-MSC induced an expansion of highly suppressive naive CD4(+)CD25(high)CD45RA(+)CD62L(+) T-regulatory cells, which may extend their allosuppressive effect. CONCLUSIONS. Our data suggest that CD271-MSC exert potent allosuppressive properties and therefore can be used as a reasonable alternative to PA-MSC for the treatment of patients with graft-versus-host disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21905954     DOI: 10.3109/14653249.2011.605118

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  12 in total

1.  Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression.

Authors:  Zyrafete Kuçi; Julia Seiberth; Hatixhe Latifi-Pupovci; Sibylle Wehner; Stefan Stein; Manuel Grez; Halvard Bönig; Ulrike Köhl; Thomas Klingebiel; Peter Bader; Selim Kuçi
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

Review 2.  CD271 as a marker to identify mesenchymal stem cells from diverse sources before culture.

Authors:  María Álvarez-Viejo; Yolanda Menéndez-Menéndez; Jesús Otero-Hernández
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

3.  Mesenchymal stem cell transfusion for desensitization of positive lymphocyte cross-match before kidney transplantation: outcome of 3 cases.

Authors:  G Saadi; F Fadel; M El Ansary; S Abd El-Hamid
Journal:  Cell Prolif       Date:  2013-04       Impact factor: 6.831

4.  Age-related yield of adipose-derived stem cells bearing the low-affinity nerve growth factor receptor.

Authors:  Raquel Cuevas-Diaz Duran; Maria Teresa González-Garza; Alejandro Cardenas-Lopez; Luis Chavez-Castilla; Delia Elva Cruz-Vega; Jorge E Moreno-Cuevas
Journal:  Stem Cells Int       Date:  2013-11-24       Impact factor: 5.443

5.  Markers for characterization of bone marrow multipotential stromal cells.

Authors:  Sally A Boxall; Elena Jones
Journal:  Stem Cells Int       Date:  2012-05-14       Impact factor: 5.443

Review 6.  Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far?

Authors:  Rodrigo Haddad; Felipe Saldanha-Araujo
Journal:  Biomed Res Int       Date:  2014-06-16       Impact factor: 3.411

7.  Characterization of bone marrow mononuclear cells on biomaterials for bone tissue engineering in vitro.

Authors:  Dirk Henrich; René Verboket; Alexander Schaible; Kerstin Kontradowitz; Elsie Oppermann; Jan C Brune; Christoph Nau; Simon Meier; Halvard Bonig; Ingo Marzi; Caroline Seebach
Journal:  Biomed Res Int       Date:  2015-02-23       Impact factor: 3.411

8.  Comparison of Characteristics of Human Amniotic Membrane and Human Adipose Tissue Derived Mesenchymal Stem Cells.

Authors:  Khadijeh Dizaji Asl; Hajar Shafaei; Jafar Soleimani Rad; Hojjat Ollah Nozad
Journal:  World J Plast Surg       Date:  2017-01

Review 9.  Autologous cell-based therapy for treatment of large bone defects: from bench to bedside.

Authors:  R Verboket; M Leiblein; C Seebach; C Nau; M Janko; M Bellen; H Bönig; D Henrich; I Marzi
Journal:  Eur J Trauma Emerg Surg       Date:  2018-01-19       Impact factor: 3.693

10.  Fibrous Demineralized Bone Matrix (DBM) Improves Bone Marrow Mononuclear Cell (BMC)-Supported Bone Healing in Large Femoral Bone Defects in Rats.

Authors:  René D Verboket; Tanja Irrle; Yannic Busche; Alexander Schaible; Katrin Schröder; Jan C Brune; Ingo Marzi; Christoph Nau; Dirk Henrich
Journal:  Cells       Date:  2021-05-19       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.